Growth Investment Growth equity funding from 1315 Capital signals external validation and capital for scale-up. Target sales opportunities include expanded manufacturing capacity, accelerated product development for new delivery platforms, and greater geographic reach in consumer health and prescription segments.

Contract Manufacturing State-of-the-art facility and emphasis on development and manufacturing expertise position USpharma as a potential CDMO partner for other pharma companies seeking dosage forms like Nitro-Dur or Cushion Grip and for pharmaceutically-equivalent products.

Diverse Portfolio Portfolio spans consumer health and prescription markets with brand and equivalent products, creating cross-sell opportunities for packaging, formulation development, regional distribution, and regulatory support across multiple markets.

Strategic Partners Active partner-oriented messaging and external product references (Nitro-Dur, Prasugrel, Methylphenidate) indicate openness to licensing, co-development, or distribution partnerships that can unlock new geographies and product lines.

Market Positioning Mid-sized scale with revenue in the low tens of millions and a multinational posture offers entry points for tier-2/3 pharmaceutical distributors, specialty pharmacies, and regional healthcare providers seeking reliable manufacturing partners with quality assurance and compliance.